Taken together, our findings indicate that the linc-UFC1 expression signature may serve as a novel biomarker for the diagnosis and prognosis of cervical cancer, and it is also highlighted that the E2F1-linc-UFC1/miR-34a/FOXP3 axis may be a potentially therapeutic target of cervical cancer.
The low expression of miR-34a in patients with cervical cancer was correlated with the degree of tumor differentiation, lymph node metastasis and the International Federation of Gynecology and Obstetrics staging.
MiR-21-5p upregulation, miR-34a downregulation, and hTERC amplification were associated with the aggressive progression of CC, which suggests that miR-21-5p, miR-34a and hTERC might serve as surrogate markers for CC progression and potential molecular targets for blockage of the development of CC.
In conclusion, the finding that the <i>CA9</i> SNP rs1048638 exerts its action through duplexes of the miR-34a and <i>CA9</i> 3'-UTRs and plays a vital role in cervical cancer in Taiwanese women may be applicable to translational medicine.
In this study, we sought to examine the hypothesis that neoadjuvant chemotherapy (NAC) is a better approach with improved prognosis and outcomes after laparoscopical radical hysterectomy (LRH) on patients with cervical cancer and to elucidate the potential roles of the p53:miR-34a:E2F1 and the p53:miR-605:Mdm2 signaling pathways in this therapy.
pri-miR-34a expression was significantly reduced in CIN and cervical cancer compared with normal cervical epithelium, as well as in CIN 2 and CIN 3 compared with CIN I.